Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 2Nasopharyngeal Carcinoma 1Multiple Myeloma 1Glioblastoma 1Brain Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 28enzalutamide 27Specimen Handling 21apalutamide 18Androgen Antagonists 16Prednisone 15Abiraterone Acetate 15Radiosurgery 13abiraterone 11Radiotherapy 10Docetaxel 10Biopsy 9darolutamide 8Pluvicto 8Nivolumab 8niraparib 6cabazitaxel 6Surveys and Questionnaires 6Radiation 6Lutetium-177 62-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 6gallium 68 PSMA-11 5bicalutamide 5Radiotherapy, Intensity-Modulated 5Lutetium 5Gonadotropin-Releasing Hormone 5radium Ra 223 dichloride 4pembrolizumab 4luprolide acetate gel depot 4cabozantinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Prostatic Neoplasms × fluciclovine F-18 × 30 days × Clear all
NCT07569926 2026-06-02

Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence

Blue Earth Diagnostics

Phase 4 Not yet recruiting
142 enrolled
Genitourinary

Prostatic Neoplasms

NCT04423211 2026-05-15

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Eastern Cooperative Oncology Group

Phase 3 Recruiting
804 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡